Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-11 23:20 | 2026-03-10 | XENE | Xenon Pharmaceuticals Inc. | DiFabio Andrea | Officer | OPT+S | $60.11 | 2,607 | $156,702 | 4,893 |
| 2026-03-11 23:21 | 2026-03-10 | XENE | Xenon Pharmaceuticals Inc. | KENNEY CHRISTOPHER JOHN | Officer | OPT+S | $60.11 | 2,771 | $166,559 | 4,729 |
| 2026-03-11 23:31 | 2026-03-11 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $539.54 | 9,500 | $5,125,647 | 130 |
| 2026-03-11 21:27 | 2026-03-09 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Director | SELL | $19.09 | 688,788 | $13,149,307 | 4,774,058 |
| 2026-03-11 21:32 | 2026-03-09 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Officer | OPT+S | $30.07 | 40,000 | $1,202,636 | 25,000 |
| 2026-03-11 16:50 | 2026-03-10 | AQST | Aquestive Therapeutics Inc. | Jung Cassie | Officer | SELL | $4.17 | 45,791 | $191,086 | 274,980 |
| 2026-03-11 16:51 | 2026-03-10 | AQST | Aquestive Therapeutics Inc. | Korczynski Sherry | Officer | SELL | $4.17 | 15,741 | $65,687 | 241,117 |
| 2026-03-11 16:51 | 2026-03-10 | AQST | Aquestive Therapeutics Inc. | TOTH A ERNEST JR | Officer | SELL | $4.17 | 58,254 | $243,094 | 376,112 |
| 2026-03-11 16:52 | 2026-03-10 | AQST | Aquestive Therapeutics Inc. | Cioffi Melina | Officer | SELL | $4.17 | 25,311 | $105,623 | 274,867 |
| 2026-03-11 16:52 | 2026-03-10 | AQST | Aquestive Therapeutics Inc. | BRAENDER LORI J | Officer | SELL | $4.17 | 40,102 | $167,346 | 442,879 |
| 2026-03-11 16:52 | 2026-03-10 | AQST | Aquestive Therapeutics Inc. | Barber Daniel | Officer | SELL | $4.17 | 180,677 | $753,965 | 1,004,753 |
| 2026-03-11 16:52 | 2026-03-10 | AQST | Aquestive Therapeutics Inc. | Boyd Peter E. | Officer | SELL | $4.17 | 29,814 | $124,414 | 338,509 |
| 2026-03-11 13:54 | 2026-03-06 | INDV | Indivior Pharmaceuticals, Inc. | Kingsley Stuart A | Director | BUY | $31.87 | 940 | $29,953 | 5,582 |
| 2026-03-11 12:12 | 2026-03-09 | INDV | Indivior Pharmaceuticals, Inc. | Ryan Barbara | Director | BUY | $32.56 | 31 | $1,009 | 5,716 |
| 2026-03-10 20:08 | 2026-03-06 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $19.22 | 100,000 | $1,922,400 | 964,161 |
| 2026-03-10 21:48 | 2026-03-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $26.84 | 2,171 | $58,270 | 82,489 |
| 2026-03-10 21:02 | 2026-03-10 | EDSA | Edesa Biotech, Inc. | Nijhawan Pardeep | Director, Officer, 10% owner | BUY | $6.60 | 1,000 | $6,599 | 628,813 |
| 2026-03-10 20:51 | 2026-03-06 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | Officer | SELL | $21.87 | 9,526 | $208,312 | 66,820 |
| 2026-03-10 23:03 | 2025-08-27 | VTRS | Viatris Inc | SIMMONS DAVID S | Director | BUY | $10.42 | 499 | $5,202 | 1,183 |
| 2026-03-10 21:33 | 2026-03-06 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Director | BUY | $15.06 | 3,000 | $45,180 | 11,500 |
| 2026-03-10 20:12 | 2026-03-09 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Horich William Todd | Officer | OPT+S | $54.50 | 8,877 | $483,797 | 0 |
| 2026-03-10 22:47 | 2026-03-09 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $16.08 | 6,693 | $107,633 | 451,815 |
| 2026-03-10 22:00 | 2026-03-09 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $60.72 | 7,931 | $481,570 | 391,673 |
| 2026-03-10 20:06 | 2026-03-06 | ANIP | Ani Pharmaceuticals Inc. | Davis Krista | Officer | SELL | $74.33 | 6,572 | $488,474 | 51,946 |
| 2026-03-10 20:09 | 2026-03-06 | ANIP | Ani Pharmaceuticals Inc. | Mutz Christopher | Officer | SELL | $74.19 | 5,723 | $424,617 | 94,471 |
| 2026-03-11 01:30 | 2026-03-10 | MNKD | MANNKIND CORP | Castagna Michael | Director, Officer | BUY | $2.59 | 100,000 | $259,000 | 2,575,911 |
| 2026-03-11 00:58 | 2026-03-06 | NAMS | NewAmsterdam Pharma Co N.V. | LANGE LOUIS G | Director | SELL | $29.41 | 28,186 | $828,950 | 0 |
| 2026-03-10 23:35 | 2026-03-02 | WHWK | Whitehawk Therapeutics, Inc. | BALL BRYAN | Officer | OPT+S | $3.31 | 1,834 | $6,070 | 206,019 |
| 2026-03-10 23:36 | 2026-03-02 | WHWK | Whitehawk Therapeutics, Inc. | Giacobello Scott M. | Officer | OPT+S | $3.31 | 2,594 | $8,585 | 28,100 |
| 2026-03-10 23:36 | 2026-03-02 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | Director, Officer | OPT+S | $3.31 | 5,100 | $16,879 | 44,579 |
| 2026-03-10 22:03 | 2026-03-09 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | SELL | $60.72 | 2,907 | $176,513 | 138,629 |
| 2026-03-10 22:05 | 2026-03-09 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | SELL | $60.72 | 2,582 | $156,779 | 47,858 |
| 2026-03-10 22:15 | 2026-03-06 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer | SELL | $29.58 | 10,000 | $295,839 | 51,000 |
| 2026-03-10 22:20 | 2026-03-10 | VKTX | Viking Therapeutics, Inc. | Aubuchon Neil William | Officer | BUY | $33.50 | 4,475 | $149,913 | 4,475 |
| 2026-03-10 20:33 | 2026-03-06 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $477.67 | 9,500 | $4,537,853 | 130 |
| 2026-03-10 20:34 | 2026-03-09 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $518.03 | 9,500 | $4,921,276 | 130 |
| 2026-03-10 20:30 | 2026-03-06 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | OPT+S | $98.99 | 30,000 | $2,969,550 | 324,879 |
| 2026-03-10 20:13 | 2026-03-09 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Mottola Frank | Officer | OPT+S | $53.65 | 1,623 | $87,074 | 18,440 |
| 2026-03-09 20:09 | 2026-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Savage Brian | Officer | OPT+S | $31.67 | 1,127 | $35,690 | 10,914 |
| 2026-03-09 20:10 | 2026-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Jover Placid | Officer | OPT+S | $31.67 | 14,150 | $448,108 | 6,774 |
| 2026-03-09 20:05 | 2026-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Shields Matthew | Officer | OPT+S | $31.67 | 17,295 | $547,705 | 9,989 |
| 2026-03-09 20:07 | 2026-03-05 | RAPP | Rapport Therapeutics, Inc. | Gault Cheryl | Officer | SELL | $28.93 | 2,014 | $58,265 | 169,914 |
| 2026-03-09 20:12 | 2026-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | Officer | OPT+S | $31.67 | 17,295 | $547,705 | 85,755 |
| 2026-03-09 20:36 | 2026-03-06 | LYEL | Lyell Immunopharma, Inc. | ARCH Venture Partners IX, LLC | 10% owner | BUY | $25.61 | 488,090 | $12,499,985 | 1,426,528 |
| 2026-03-09 20:05 | 2026-03-06 | ARVN | Arvinas Inc. | Morrison Briggs | Director | BUY | $13.40 | 20,000 | $268,070 | 96,021 |
| 2026-03-09 20:12 | 2026-03-05 | AGIO | Agios Pharmaceuticals Inc. | Viswanadhan Krishnan | Officer | OPT+S | $27.80 | 2,959 | $82,260 | 5,141 |
| 2026-03-09 20:06 | 2026-03-05 | XNCR | Xencor Inc | Cornelissen Bart Jan | Officer | SELL | $11.25 | 2,517 | $28,305 | 79,397 |
| 2026-03-09 20:06 | 2026-03-05 | XNCR | Xencor Inc | Eckert Celia | Officer | SELL | $11.17 | 5,011 | $55,952 | 76,918 |
| 2026-03-09 20:07 | 2026-03-05 | XNCR | Xencor Inc | Desjarlais John R | Officer | SELL | $11.16 | 6,620 | $73,881 | 263,831 |
| 2026-03-09 20:06 | 2026-03-05 | XNCR | Xencor Inc | Dahiyat Bassil I | Director, Officer | SELL | $11.18 | 21,476 | $240,016 | 546,316 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.